To include your compound in the COVID-19 Resource Center, submit it here.

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE